New Retina Radio by Eyetube

Latest Episodes:

AAO '22: Biomarkers and AI in the OR Nov 10, 2022

Show notes

Identifying systemic biomarkers indicating risk for age-related macular degeneration would be a game-changer. But how can we find those biomarkers? We spoke with Joan Miller, MD, whose work with the Harvard Retina Metabolomics Program focuses on identifying specific metabolites that might be useful in real-world practice. Also, Yannek Leiderman, MD, PhD, stopped by to fill us in on the state of artificial intelligence (AI) in the OR. How far away are surgeons from interacting in real time with AI?

AAO '22 Late-Breaking Talks: Biosimilar Phase 3 Data and TRUCKEE Update Nov 03, 2022

Show notes

Phase 3 data evaluating the biosimilarity of a new biosimilar (Xlucane, Xbrane Biopharma) referencing ranibizumab (Lucentis, Genentech) has been completed. What were the results? Anat Loewenstein, MD, joined New Retina Radio to walk us through the results of the XPLORE study. And Ramanath Bhandari, MD, summarized his presentation on the TRUCKEE study, a real-world evaluation of the performance of faricimab (Vabysmo, Genentech/Roche). What do the most recent updates tell us about practice patterns and patient response?

AAO '22: GATHER2 Study Results Oct 25, 2022

Show notes

Researchers in the second pivotal study evaluating the safety and efficacy of avacincaptad pegol (Zimura, IVERIC bio) for the treatment of geographic atrophy have released 1-year results. New Retina Radio spoke with Arshad Khanani, MD, MS, about the GATHER2 study findings. How did the study results compare to the GATHER1 conclusions—and might the company move forward with a regulatory filing?

New Retina Radio Journal Club: Latest Literature in Stickler Syndrome and GRTs Oct 13, 2022

Show notes

What is the effect of laser prophylaxis in patients with Stickler Syndrome, and just how effective are buckles in patients with GRT detachments? Yoshi Yonekawa, MD, PhD, is joined by Peter Campbell, MD; Karen Jeng-Miller, MD; and Prethy Rao, MD, to review two recent contributions to the literature, during which they probe the papers' findings and explore their limitations.

New Retina Radio Journal Club: Updates in ROP Sep 30, 2022

Show notes

What changed in the most recent iteration of the International Classification of Retinopathy of Prematurity? And what do new data tell us about how ROP patients fare in adulthood? To find out, Yoshi Yonekawa, MD, PhD, is joined by Peter Campbell, MD; Karen Jeng-Miller, MD; and Prethy Rao, MD, to break down the latest literature, examine the papers' limitations, and offer pearls for surgical management of adults with history of ROP.

ASRS Meeting Coverage Day 3: DR Biomarkers and Gene Tx for Achromatopsia Sep 15, 2022

Show notes

Can a quantitative analysis of OCT images detect early diabetic retinopathy in patients without symptoms? New Retina Radio spoke with Jennifer Lim, MD, whose research team sought to learn whether imaging analyses of photoreceptor length and reflectivity parameters could serve as a biomarker for disease detection.

We also sat down with Lejla Vajzovic, MD, who shared data on a pair of phase 1 studies assessing the safety and efficacy of two gene therapies for achromatopsia. One of those two drugs will be going on for further study. Which one? Stick with us to find out.

New Retina Radio Journal Club: Multifocal, Indolent, Nonprogressive Choroidal Lesions Aug 25, 2022

Show notes

Retina specialists may wish to turn to the literature to learn more about multifocal, indolent, nonprogressive choroidal lesions. Let the New Retina Radio Journal Club with VBS help you out. Moderator Kyle Kovacs, MD, is joined by Cynthia Qian, MD, and David Xu, MD, to review two recent papers on this atypical presentation.

ASRS Meeting Coverage: Day 2 Aug 04, 2022

Show notes

Was treat-and-extend faricimab (Vabysmo, Genentech) an effective means of controlling DME in the YOSEMITE and RHINE studies? New Retina Radio spoke with John Kitchens, MD, whose ASRS presentation reviewed results from a pair of phase 3 studies that assessed, in part, 12- and 16-week dosing intervals of faricimab in patients with DME.

Also joining us is Michael Allingham, MD, PhD. He shared results from the phase 2b ZETA-1 study, which examined the safety and efficacy of APX3330 (Ocuphire Pharma), an oral medication for DR. What promise might this treatment hold? Tune in to learn more.

This editorially independent podcast is supported with advertising.

ASRS Meeting Coverage: Day 1 Jul 28, 2022

Show notes

Treat-and-extend regimens has been used for thousands of wet AMD patients. How does brolucizumab (Beovu, Novartis) stack up when compared with aflibercept (Eylea, Regeneron) in a matched treat-and-extend study? New Retina Radio spoke with Carl Regillo, MD, a member of the TALON study group, which sought to find out if brolucizumab was superior to aflibercept for extending treatment intervals in wet AMD patients.

We also spoke with Carl Danzig, MD, whose work on the TRUCKEE study illuminates real-world treatment dynamics when it comes to the use of faricimab (Vabysmo, Genentech) in wet AMD treatment. How are patients responding in the real world?

New Retina Radio Journal Club: Recurrent RRD Management Jul 14, 2022

Show notes

How might two recent contributions to the literature deepen our understanding of recurrent rhegmatogenous retinal detachment (RRD)? To find out, moderator Kyle Kovacs, MD, is joined by panelists Cynthia Qian, MD, and David Xu, MD, to review a pair of papers on the topic. After the break, the group tackles tamponade selection and use of scleral buckles in patients with RRD, and discusses tactics for bringing a patient back to the OR if RRD recurs.

This editorially independent podcast is supported with advertising.

Our TOPPODCAST Picks

Follow Us

Stay Connected

New Retina Radio by Eyetube

Related Podcasts

Links

Stay Connected